In 2015, The Nei-funded Diabetic Retinopathy Clinical Research Network (drcr.net) Showed That Eye Injections Of The Anti-vegf Drug Lucentis (ranibizumab) Are Highly Effective In Treating Proliferative Diabetic Retinopathy.

Ivey-Foster emphasized, I would say to anyone that has diabetes, make sure you get regular eye exams. In addition to early detection, her experience highlights the importance of timely treatment. Research reveals new treatment options Today, people like Ivey-Foster have an alternative to laser therapy. In 2015, the NEI-funded Diabetic Retinopathy Clinical Research Network (DRCR.net) showed that eye injections of the anti-VEGF drug Lucentis (ranibizumab) are highly effective in treating proliferative diabetic retinopathy. VEGF is what stimulates abnormal blood vessel growth and leakage in the retina. http://advisingeyesurgeon.beatthetrain.org/2016/12/05/the-top-information-on-choosing-critical-criteria-of-eye-bags/The finding was the first major treatment advance for proliferative diabetic retinopathy in 40 years . In 2016, the DRCR.net reported results of a clinical trial that compared three anti-VEGF drugs for diabetic macular edema, a complication of diabetic retinopathy that causes the build-up of fluid in a region of the retina called the macula. http://advisingeyesurgeon.beatthetrain.org/2016/12/05/getting-advice-on-swift-products-in-eye-surgery/The study found that Lucentis, Avastin (bevacizumab), and Eylea (aflibercept) were similarly effective when patients vision loss was mild. Eylea outperformed Avastin and Lucentis among patients who started treatment with moderate (20/50) or worse vision. There has never been a more hopeful time in the treatment of diabetic retinopathy, said Dr. Huang, a member of the DRCR.net.

For the original version including any supplementary images or video, visit http://www.newswise.com/articles/view/665152/?sc=rsmn

Leave a Reply

Your email address will not be published. Required fields are marked *